Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for Post-stroke Depression
NCT05932550Phase 2Completed
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of maraviroc in major depressive disorder (MDD), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 10 weeks. Started Aug 2020; status: completed.
02
Drugs
maraviroc
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05932550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932550.